Q3 2025 Invivyd Inc Earnings Call Transcript
Key Points
- Invivyd Inc (IVVD) raised approximately $87 million in capital, leaving the company well-funded to execute its pivotal clinical program and expand its commercial organization.
- The company received positive feedback from the US FDA to develop its vaccine alternative antibody, VYD2311, for broad populations not adequately served by current COVID vaccines.
- PEMGARDA revenues grew by 11% quarter on quarter and 41% year over year, reflecting successful market awareness efforts.
- Invivyd Inc (IVVD) has over 15,000 contracted GPO sites and more than 1,200 sites offering infusion, with 76% of those accounts reordering.
- The company is exploring early-stage discovery efforts in RSV and measles, with plans to provide updates before the end of the year.
- The company acknowledges that PEMGARDA has less attractive properties in terms of scalability and accessibility compared to future products.
- There is a lack of modern randomized data describing current or long-term vaccine efficacy, which Invivyd aims to address with its studies.
- The commercial uptake of COVID vaccines is substantially below that of influenza vaccines, indicating potential market challenges.
- Concerns about side effects are a significant barrier to COVID vaccine uptake, which Invivyd aims to address with its antibody-based approach.
- The coordination required for the LIBERTY study involves logistical challenges due to the combination of prophylactic medicines in a single clinical study.
Good morning, everyone, and welcome to the Q3 2025 Invivyd earnings conference call. (Operator Instructions)
Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Katie Falzone, Senior Vice President of Finance. Please go ahead.
Thank you, operator. A short while ago, we issued a press release announcing our Q3 2025 financial results in recent business highlights. That press release and the slides that are being used on today's webcast can be found in the investors section of the Invivyd website under the press release and events and presentation sections respectively. Today's discussion will be led by Mark Elia, Chairman of Invivyd's Board of Directors. He is joined by Tim Lee, Chief Commercial Officer; and Bill Duke, Chief Financial Officer.
During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
